Ceribell, Inc. is a commercial-stage medical technology company. It is focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.
BörsenkürzelCBLL
Name des UnternehmensCeribell Inc
IPO-datumOct 11, 2024
CEOMs. Xingjuan (Jane) Chao, Ph.D.
Anzahl der mitarbeiter281
WertpapierartOrdinary Share
GeschäftsjahresendeOct 11
Addresse360 N. Pastoria Avenue
StadtSUNNYVALE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94085
Telefon18004360826
Websitehttps://ceribell.com/
BörsenkürzelCBLL
IPO-datumOct 11, 2024
CEOMs. Xingjuan (Jane) Chao, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten